Compare Incyte Corporation (INCY) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Otis Worldwide Corp — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Otis Worldwide Corp trades at $65.95 (market cap $25.17B). The key difference: Incyte Corporation and Otis Worldwide Corp are close in size by market cap, and Otis Worldwide Corp pays a 2.66% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Otis Worldwide Corp for 66 Days on average.
| INCY | OTIS | |
|---|---|---|
Market Cap | $22.85B | $25.17B |
Volume | 1,927,029 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $129.93 | $93.62 |
52-Week Low | $83.80 | $64.05 |
Typical Hold Time | 33 Days | 66 Days |
Enterprise Value | $18.35B | $33.20B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Otis Worldwide trades at $66.11, near its 52-week low, with a bearish technical signal and recent earnings misses in Q4 2025, Q1 2026, and Q2 2026. The company maintains stable revenue around $14.4B in 2025 but faces margin pressure, with net income margin at 10.17%. Analyst consensus is split between Buy and Hold, with a price target of $87.00, indicating potential upside. Recent news highlights CEO succession plans and challenges in China demand.
The outlook for Otis hinges on service margin recovery and China market stabilization. Investment opportunities include its dominant market position and durable cash flow from service contracts, but risks involve persistent cost pressures, high debt levels, and weak equipment demand. Wall Street remains cautiously optimistic given the valuation discount to targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
